Aileron Overcoming Spirited Debate About Stapled Peptides
This article was originally published in The Pink Sheet Daily
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
You may also be interested in...
The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.
GPCR-focused Heptares and the protein scaffold company Complix complete a seemingly rare event for European biotechs, a second round of VC funding.
At Elsevier Business Intelligence's recent Therapeutic Area Partnerships conference, a roundtable of senior pharmaceutical executives and entrepreneurs weighed in on industry’s current funding challenges, how dealmaking defines a biotech’s ambitions and strategy, and pharma’s appetite for early-stage innovation.